Aspira Women’s Health: KOL Event on Aspira’s Approach to Ameliorating Ovarian Cancer Risk Assessment

08/24/2022 - 08/24/2022
12:00 pm - 1:00 pm EDT
The event will feature presentations from Key Opinion Leaders (KOLs) Nicole E. Williams, MD, FACOG, FACS (The Gynecology Institute of Chicago) and Gerard P. Reilly, MD (Director of Clinical Research and Innovation, Axia Women’s Health).
Dr. Williams will discuss how Aspira’s OVA1Plus has the potential to help further stratify patients’ risk of malignancy. OVA1Plus combines OVA1 (an FDA cleared multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index) and Overa (generation multivariate index assay) to maximize the rate of detection for risk of malignancy and minimize the falsely elevated rate in the intermediate range.
Dr. Reilly will discuss how Aspira’s new OvaWatch algorithm in the detection of ovarian cancer may serve as a novel strategy to help assess treatment strategies and address the current limitations present in the biomarker-based blood test landscape, with the overall goal of improving health outcomes for women with ovarian cancer.
A live question and answer session will follow.